Tetra Discovery Partners Secures $5,000,000 Series A Funding Round
Feed Type
Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=6edca247-7e61-4b81-93d4-175e0124b334
Date 11/30/2016
Company Name Tetra Discovery Partners
Mailing Address 910 Rosewood Avenue SE Grand Rapids, MI 49506 USA
Company Description Our research focuses on developing new treatments for depression based on subtype-selective modulation of phosphodiesterase 4B (PDE4B). PDE4 in neurons is responsible for the hydrolysis of cAMP. We and our colleagues recently described the protein structure of a key PDE4 regulatory domain known as UCR2.
Proceeds Purposes We are very pleased to receive this new financing which will enable Tetra to complete the necessary preparations for a planned Phase 2a study of our lead drug candidate, BPN14770, in Alzheimer’s disease during the second half of 2017.